Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Well-Differentiated Neuroendocrine Carcinoma”

79 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 79 results

Testing effectiveness (Phase 2)Ended earlyNCT03630120
What this trial is testing

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, MedullaryDifferentiated Thyroid Cancer+3 more
H. Lee Moffitt Cancer Center and Research Institute 6
Testing effectiveness (Phase 2)Looking for participantsNCT06395402
What this trial is testing

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2
University of Iowa 120
Testing effectiveness (Phase 2)Study completedNCT02250885
What this trial is testing

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Who this might be right for
Carcinoma, Neuroendocrine
Gabrail Cancer Center Research 14
Not applicableStudy completedNCT03616431
What this trial is testing

Pancreatic Cancer Dietary Assessment Study

Who this might be right for
Pancreatic NeoplasmPancreas AdenocarcinomaWell-Differentiated Neuroendocrine Carcinoma+1 more
The Christie NHS Foundation Trust 112
Testing effectiveness (Phase 2)Ended earlyNCT00843531
What this trial is testing

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University of California, San Francisco 17
Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
Not applicableStudy completedNCT02592356
What this trial is testing

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaMalignant Adrenal Gland PheochromocytomaMalignant Paraganglioma+1 more
M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Looking for participantsNCT05746208
What this trial is testing

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco 29
Testing effectiveness (Phase 2)Study completedNCT03290079
What this trial is testing

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT00118248
What this trial is testing

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Recurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid Cancer+1 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Active Not RecruitingNCT04514497
What this trial is testing

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Who this might be right for
Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine Carcinoma+9 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT05247905
What this trial is testing

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorUnresectable Pancreatic Neuroendocrine Carcinoma
Alliance for Clinical Trials in Oncology 31
Not applicableStudy completedNCT04452292
What this trial is testing

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

Who this might be right for
Large-Cell Neuroendocrine Carcinoma
Charles Kunos 2
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Looking for participantsNCT06472388
What this trial is testing

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsProgressionNeuroendocrine Tumor Grade 1+4 more
AC Camargo Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Large-scale testing (Phase 3)Looking for participantsNCT06855095
What this trial is testing

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2+1 more
The Netherlands Cancer Institute 39
Not applicableUnknownNCT00687778
What this trial is testing

11C-Acetate PET/CT Non-FDG-Avid Tumors

Who this might be right for
Soft Tissue SarcomasThyroid CancerLung Cancer+7 more
Tel-Aviv Sourasky Medical Center 100
Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33
Load More Results
189